Sodium valproate and thrombocytopenia.

Area of Science:

• Neurology
• Hematology
• Pediatrics

Background:

• Sodium valproate is a widely used antiepileptic and mood-stabilizing drug.
• Thrombocytopenia, a condition characterized by a low platelet count, is a known but infrequent adverse effect of sodium valproate therapy.

Observation:

• A case study of a 6-year-old boy receiving sodium valproate is presented.
• The patient developed progressive thrombocytopenia starting 6 months after initiating the medication, persisting until 16 months of age.

Findings:

• Despite the continuation of sodium valproate due to its therapeutic efficacy, the boy's platelet count spontaneously normalized.
• No clinical signs of bleeding or hemorrhagic complications were observed during the period of thrombocytopenia.

Implications:

• Periodic monitoring of platelet counts is advisable for patients on sodium valproate.
• Thrombocytopenia in patients on sodium valproate may not necessitate immediate drug discontinuation if clinically asymptomatic.